BioCryst Pharmaceuticals,Inc. (BCRX)

[Fress]

From March 10-2020 Companies Presentation: Page 15

COVID-19 Antiviral Status Update: Galidesivir (BCX4430)


$82 M of program support to date:
1 Warren, T. K. et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402-405, doi:10.1038/nature13027 (2014)

• Recurring global health crises from emerging viral infections highlight the
critical need for broad spectrum antivirals in government stockpiles to
protect public health

• Galidesivir has shown activity against >20 RNA viruses in 9 different
families, including coronaviruses1
• Activity against COVID-19 coronavirus

• Galidesivir was safe and generally well tolerated in two Phase 1 trials
• Development has progressed to clinical trial in Yellow Fever

BioCryst working with the U.S. government to explore:
• In vitro testing against COVID-19 virus
• Advancing to clinical trial in COVID-19
• Increasing drug supply


$BCRX